Research Overview of Nebivolol
Nebivolol is a highly selective beta-1 adrenergic receptor antagonist that represents third-generation beta-blocker pharmacology for cardiovascular research applications. Unlike traditional beta-blockers, nebivolol demonstrates unique dual mechanisms through selective beta-1 blockade combined with nitric oxide-mediated vasodilation properties. This compound exhibits exceptional selectivity ratios for beta-1 over beta-2 receptors, making it valuable for investigating cardiac-specific adrenergic modulation without significant bronchial effects. Researchers at Stroid UK Shop utilise nebivolol to study endothelial function, vascular reactivity, and cardiac remodelling in experimental models.
Laboratory Applications
Scientists investigate nebivolol’s distinctive pharmacological profile in cardiovascular research protocols examining endothelial nitric oxide synthase activation and oxidative stress pathways. The compound’s ability to modulate both adrenergic signalling and nitric oxide bioavailability provides researchers with a unique tool for studying integrated cardiovascular mechanisms. Studies examine nebivolol’s effects on arterial compliance, left ventricular function, and metabolic parameters in various experimental frameworks. Research applications extend to investigating age-related cardiovascular changes, where nebivolol’s antioxidant properties complement its hemodynamic effects. Advanced cardiovascular researchers exploring beta-blocker pharmacology particularly value nebivolol’s preserved cardiac output characteristics during sympathetic blockade.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Nebivolol hydrochloride |
| Strength | 2.5mg per tablet |
| Manufacturer | Johnlee Pharmaceuticals |
| CAS Number | 118457-14-0 (base) |
| Molecular Formula | C₂₂H₂₅F₂NO₄ |
| Molecular Weight | 405.44 g/mol |
| Storage | Room temperature, dry conditions |
| Shelf Life | As per manufacturer labelling |
Research teams studying advanced cardiovascular pharmacology often combine nebivolol investigations with complementary research compounds available through selective androgen receptor modulators and peptide research categories for comprehensive experimental protocols.
Research Compliance Statement
Nebimax 2.5mg tablets are supplied exclusively for in-vitro laboratory research purposes and analytical reference applications. This product is not intended for human consumption, clinical use, or therapeutic applications. Researchers must ensure appropriate laboratory protocols, safety measures, and institutional approvals are in place before conducting experimental studies. All investigations should comply with relevant research guidelines and institutional review board requirements for cardiovascular research compounds.
